A Pilot, Open-label, Randomized, Two-Way Crossover, Single-Dose Bioequivalence Study of Pomalidomide Under Fasting Condition in Chinese Healthy Volunteers.

Trial Profile

A Pilot, Open-label, Randomized, Two-Way Crossover, Single-Dose Bioequivalence Study of Pomalidomide Under Fasting Condition in Chinese Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Amyloid light-chain amyloidosis; Brain cancer; Multiple myeloma; Systemic scleroderma; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors Jiangsu Simcere Pharmaceutical
  • Most Recent Events

    • 12 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top